| abstract |
The present disclosure relates to stimulating agents, pharmaceutically acceptable salts of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them, as well as phosphate ester prodrugs thereof, and increasing and/or increasing the concentration of nitric oxide (NO). Click on increasing the concentration of guanosine monophosphate (cGMP), or both, or their use in combination or alone with one or more additional agents for the treatment of various diseases where upregulation of the NO pathway is desired. will be. The compound has formula I. |